Human Control Antibodies with Mutated CDRs for Specific Binding Assays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current control antibodies used in antibody testing often produce inexplicable experimental outcomes due to their ability to interact with other antigen molecules, making it difficult to distinguish specific antigen-antibody interactions from non-specific effects, thus necessitating improved, rationally designed control antibodies.
Innovation Solution
Development of novel control antibodies with well-defined variable domains that lack antigen affinity but maintain a native antibody structure, allowing researchers to differentiate between specific and non-specific interactions, suitable for various applications including flow cytometry, immunoblotting, and therapeutic uses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional control antibodies are used, then they maintain full CDR functionality and native structure, but they produce non-specific interactions with other antigen molecules causing inexplicable experimental outcomes
Solution Approach 1:
The patent extracts the antigen-binding capability from the antibody structure by introducing mutations in the CDR regions while retaining the native antibody framework. This separation allows the control antibody to maintain structural integrity and Fc-mediated functions without the harmful non-specific antigen interactions, directly resolving the contradiction between reliability and harmful factors
Solution Approach 2:
The patent applies parameter changes by mutating specific amino acid residues in the CDR regions (e.g., changing binding affinity parameters) while preserving the overall antibody structure. This enables the control antibody to lose antigen-binding capability (reducing harmful non-specific interactions) while maintaining native structure for reliable experimental control
2Object-generated harmful factors
If control antibodies with mutated CDRs are designed to lack antigen affinity, then non-specific interactions are reduced, but it becomes difficult to maintain well-defined variable domains with native structure
Solution Approach 1:
The patent applies local quality by introducing mutations only in specific CDR regions (local areas) while leaving the framework regions and overall antibody structure unchanged. This localized modification approach reduces non-specific interactions through CDR mutations while preserving the native structure and stability of the rest of the antibody molecule
Solution Approach 2:
The patent segments the antibody into functional regions (CDRs and framework regions) and applies different modifications to each segment. The CDR segments are mutated to reduce antigen affinity, while the framework segments are preserved to maintain native structure, resolving the contradiction between reducing harmful factors and maintaining structural stability
3Device complexity
If traditional control agents like buffer are used, then the system is simple, but they cannot distinguish specific antigen-antibody interactions from non-specific effects
Solution Approach 1:
The patent introduces a specially designed control antibody as an intermediary control agent that mediates between the simplicity of buffer controls and the complexity of functional antibodies. This intermediary control antibody lacks antigen-binding capability but maintains native structure, enabling it to control for non-specific effects while preserving the ability to measure specific binding, thus resolving the contradiction between complexity and measurement precision
Data Source
AI summary
The present invention provides novel, rationally designed human control antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have well characterized variable domains that have been designed to minimize or eliminate antigen binding without altering gross antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.